Cancer vaccine - IDM S.A./Oxford BioMedica
Alternative Names: TroVax-DCLatest Information Update: 31 Dec 2021
At a glance
- Originator IDM S.A.; Oxford BioMedica
- Developer Oxford BioMedica
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer